H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Genelux Corp. today and set a price target of $31.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Emily Bodnar’s rating is based on the promising developments in Genelux Corp.’s clinical trials, particularly with their Olvi-Vec treatment. The company is making significant progress in its Phase 2 trial for recurrent non-small cell lung cancer (NSCLC), where Olvi-Vec is being tested in combination with platinum doublet and CPI. The trial’s initial data, expected in the fourth quarter of 2025, is anticipated to show improved response rates compared to existing second-line chemotherapy treatments.
Additionally, the ongoing Phase 1b/2 trial for small cell lung cancer (SCLC) in China has shown encouraging preliminary results. Patients treated with Olvi-Vec and platinum chemotherapy have demonstrated a high disease control rate and notable tumor reductions, even at lower doses. This suggests that higher doses could yield even better outcomes. The potential for Olvi-Vec to be effective in various solid tumors, along with its differentiated efficacy, supports the Buy rating for Genelux Corp.’s stock.
In another report released on October 22, Maxim Group also maintained a Buy rating on the stock with a $20.00 price target.